Back

A continuum of multifactorial benefits of icosapent ethyl.

26 August 2022 (15:45 - 15:55)
Organised by:
Congress Presentation Part of: New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice Lipid-Lowering Agents Open Access ESC Congress 2022

About the speaker

Photo
Professor Magnus Back

Karolinska University Hospital, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor L. Badimon (Barcelona, ES)
Slides Video
Presentation thumbnail
ASCVD & residual risk: recent clinical insights with icosapent ethyl.
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Integrating icosapent ethyl in clinical practice: which patients will benefit?
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Discussion.
Professor L. Badimon (Barcelona, ES)
Slides Video

Access the full session

Session thumbnail
New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 15:45 CET
You may be interested in
thumbnail
Congress Session
Primary Care and Risk Factor Management 1
13 April 2023
thumbnail
Congress Presentation
Associations of omega-3 fatty acid subclasses with cardiovascular diseases in 500,000 individuals
2 September 2024
thumbnail
Congress Presentation
Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
26 August 2023
thumbnail
Congress Presentation
Dyslipidaemias.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources